CAJ | 학술논문

目的：探讨慢病毒介导的CXCR 7-shRNA转染人胃癌细胞株SGC 7901后重楼总皂苷干预对CXCR7蛋白表达的影响。方法设计并合成CXCR7的3条shRNA序列及1条阴性对照序列，与pSilencerTM 4.1系统合成构建重组慢病毒载体，转染HEK 293 T细胞包装病毒并检测滴度；将3种重组慢病毒载体及阴性对照分别感染人胃癌细胞SGC 7901，RT-PCR检测用药前后CXCR 7 mRNA的表达情况，测定沉默效率，筛选沉默效率最高的一组CXCR 7-shRNA作为后续实验表达载体；MTT法检测转染CXCR 7-shRNA对SGC 7901细胞的增殖的影响以及重楼总皂苷干预后的影响；Western blot检测转染CXCR 7-shRNA后SGC 7901细胞蛋白表达情况以及重楼总皂苷干预的影响。结果测序证实3种慢病毒载体及1组阴性对照载体均包装成功，滴度分别4.9×108 pfu/mL、3.6×108 pfu/mL、5.2×108 pfu/mL和2.0×108 pfu/mL；3组慢病毒载体转染SGC 7901细胞后，CXCR 7 mRNA的表达量均较阴性对照组显著降低（P＜0.05），其中CXCR 7-shRNA-1组和重楼总皂苷组对CXCR7的抑制率显著高于其他2组（P＜0.05）；CXCR 7-shRNA-1转染SGC 7901后，肿瘤细胞的生长增殖显著下降，与其他组相比有显著性差异（P＜0.05）；CXCR 7-shRNA-1转染SGC 7901后，与空病毒载体组、空白组相比，CXCR 7蛋白表达量显著降低（P＜0.05）。结论成功构建了3种CXCR 7-shRNA慢病毒表达载体。转染SGC 7901细胞以及采用重楼总皂苷处理均可有效下调CXCR 7 mRNA和蛋白的表达水平，并能够抑制肿瘤细胞的增殖与侵袭。因此可认为CXCR7基因在该机制中起到了至关重要的作用，为我们进一步研究以CXCR 7/CXCL 12生物学轴为靶点的胃癌基因治疗奠定了基础。
목적：탐토만병독개도적CXCR 7-shRNA전염인위암세포주SGC 7901후중루총조감간예대CXCR7단백표체적영향。방법설계병합성CXCR7적3조shRNA서렬급1조음성대조서렬，여pSilencerTM 4.1계통합성구건중조만병독재체，전염HEK 293 T세포포장병독병검측적도；장3충중조만병독재체급음성대조분별감염인위암세포SGC 7901，RT-PCR검측용약전후CXCR 7 mRNA적표체정황，측정침묵효솔，사선침묵효솔최고적일조CXCR 7-shRNA작위후속실험표체재체；MTT법검측전염CXCR 7-shRNA대SGC 7901세포적증식적영향이급중루총조감간예후적영향；Western blot검측전염CXCR 7-shRNA후SGC 7901세포단백표체정황이급중루총조감간예적영향。결과측서증실3충만병독재체급1조음성대조재체균포장성공，적도분별4.9×108 pfu/mL、3.6×108 pfu/mL、5.2×108 pfu/mL화2.0×108 pfu/mL；3조만병독재체전염SGC 7901세포후，CXCR 7 mRNA적표체량균교음성대조조현저강저（P＜0.05），기중CXCR 7-shRNA-1조화중루총조감조대CXCR7적억제솔현저고우기타2조（P＜0.05）；CXCR 7-shRNA-1전염SGC 7901후，종류세포적생장증식현저하강，여기타조상비유현저성차이（P＜0.05）；CXCR 7-shRNA-1전염SGC 7901후，여공병독재체조、공백조상비，CXCR 7단백표체량현저강저（P＜0.05）。결론성공구건료3충CXCR 7-shRNA만병독표체재체。전염SGC 7901세포이급채용중루총조감처리균가유효하조CXCR 7 mRNA화단백적표체수평，병능구억제종류세포적증식여침습。인차가인위CXCR7기인재해궤제중기도료지관중요적작용，위아문진일보연구이CXCR 7/CXCL 12생물학축위파점적위암기인치료전정료기출。
Objective To investigate the CXCR 7 protein expression when CXCR 7-shRNA transfected into human gastric cancer cell which mediated with lentivirus vector combined with Rhizoma Paridis Total Saponin. Methods Three shRNA sequences of CXCR 7 and one negative control sequence were designed and synthesized, and recombinant lentiviral vectors with pSilencerTM 4.1 system were established. Transfection of HEK 293 T cells and packaging viral were finished and the titers were detected. Transfection of all recombinant lentiviral vectors and negative control vector were finished and expression of CXCR 7 mRNA were detected by RT-PCR method. Silence efficiency in groups were determined and the expression vector with highest silence efficiency was selected for next experiments. To detect the effect of SGC 7901 cell proliferation by CXCR 7-shRNA transfection and combined with Rhizoma Paridis Total Saponin intervention with MTT. To detect the effect of SGC 7901 cell expression of protein by CXCR 7-shRNA transfection and combined with Rhizoma Paridis Total Saponin intervention with Western blot. Results The packaging of three lentiviral vector and negative control sequence are successful which is confirmed by gene sequencing and the titer are 4.9×108 pfu/mL, 3.6×108 pfu/mL, 5.2×108 pfu/mL, 2.0×108 pfu/mL respective. The expression quantity of CXCR 7 mRNA in positive groups are lower than negative control group(P<0.05)and inhibition ratio to CXCR 7 in CXCR 7-shRNA-1 and combined with Rhizoma Paridis Total Saponin intervention group is higher than the other two groups(P<0.05). The proliferation level of tumour cell is significant reduction after CXCR 7-shRNA-1 transfection and have a significant difference comparing to the group without transfection(P<0.05). The expression of CXCR 7 protein is significant reduction after CXCR 7-shRNA-1 transfection comparing to the group without virus vector and negative control group and have a significant difference(P<0.05). Conclusion The construction of three CXCR 7-shRNA lentiviral expression vector are successful and expression level of protein and CXCR 7 mRNA are down-regulated effectively after transfection and combined with Rhizoma Paridis Total Saponin intervention. It maybe means that CXCR 7 gene takes an important role in the process of gastric cancer proliferation and invasion.This is foundation for further study of gastric cancer gene therapy using CXCR 7/CXCL 12 biological axis as a target.